Enasidenib

Overall survival by IDH2 mutant allele in late-stage R/R AML patients enrolled in IDHENTIFY

Trends in AML and MDS at ASH 2021

Genomic updates in the field of MPNs

Updates on IDH inhibition in AML

Higher-risk MDS in 2021: pevonedistat, sabatolimab & APR-246

MDS clinical trials: the European effort

Enasidenib plus azacitidine in newly-diagnosed AML

AML post-transplant maintenance: enasidenib & ivosidenib

AML: new targeted inhibitors as single agents?

Enasidenib for IDH2-mutated MDS

Progress in AML & research at the University of Düsseldorf

Personalized AML therapy with John Byrd: the beat AML trial and more

Ivosidenib or enasidenib with chemotherapy for AML produces deep remissions

Beat AML: promising results with enasidenib for AML in the frontline

IDH inhibitors for AML: highlights from ASH 2018

IDH1/2 inhibitors for upfront AML therapy and transfusion independence